EWA
ATNM icon

EverSource Wealth Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

EverSource Wealth Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16
Closed -$22 – 4393
2025
Q4 		$22 Sell
16
-70
-81% -$102 ﹤0.01% 4216
2025
Q3 		$138 Sell
86
-129
-60% -$210 ﹤0.01% 4154
2025
Q2 		$301 Buy
215
+47
+28% +$70 ﹤0.01% 3997
2025
Q1 		$271 Buy
168
+94
+127% +$119 ﹤0.01% 3624
2024
Q4 		$93 Buy
+74
New +$115 ﹤0.01% 3552

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverSource Wealth Advisors's ATNM Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q1 2026, closing a stake of 16 shares — an estimated $22 sold.

EverSource Wealth Advisors first reported a position in ATNM in Q4 2024 and held it in 5 quarters. The position peaked at $301 in Q2 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • EverSource Wealth Advisors reported no remaining Actinium Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • EverSource Wealth Advisors sold 16 Actinium Pharmaceuticals shares in Q1 2026, an estimated $22.
  • EverSource Wealth Advisors first reported a position in Actinium Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • EverSource Wealth Advisors's Actinium Pharmaceuticals position peaked at $301 in Q2 2025.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.